恒敬生物根植于公司核心團(tuán)隊(duì)20多年的全球研發(fā)積累，創(chuàng)建國際領(lǐng)先的生物制藥企業(yè)，自創(chuàng)成熟、高效、大規(guī)模、成本極具競(jìng)爭(zhēng)力的生物醫(yī)藥產(chǎn)品，產(chǎn)品涵蓋胰島素類藥物、GLP-1類藥物以及更多的蛋白類、多肽類產(chǎn)品，位于嘉興的先進(jìn)工廠一期設(shè)計(jì)產(chǎn)能3噸原液和過億支制劑，二期原液產(chǎn)能超10噸。

Virtu Pharmako is a leading biopharmaceutical company with R&D, regulatory submission and CGMP manufacture engaged in four major business areas: Insulin drug portfolio, GLP-1 drug portfolio, biosynthetic technique corporations and varieties of protein/polypeptide bioproducts.

With more than 20 years of global R&D study and commercial experiences, the company established the unique, innovative biotechnology platform which efficiently developed dozens of cost-competitive, environment friendly and commercial-scale biomedical products.

Our state-of-art, world leading biopharmaceutical manufacture facility with building area 1 Million ft2 is built up in Jiaxing, Zhejiang, China, where located in near Metropolitan City, Shanghai. In Phase I, the production capacity includes 3 metric tonnes per year of API and over 120 million units per year of injectable. Production capacity of Phase II will surpasses 10 metric tonnes of API.